Combination of mitoxantrone, topotecan and cytarabine in patients with refractory or relapsed AML or CML in blast crisis.

被引：0
|
作者：
Hoechsmann, B [1 ]
Döhner, H [1 ]
Ganser, A [1 ]
Heil, G [1 ]
Einsele, H [1 ]
Raghavachar, A [1 ]
Hoelzer, D [1 ]
Bergmann, L [1 ]
机构：
[1] Univ Ulm, Dept Hematol Oncol, Ulm, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1402
引用
收藏
页码：325A / 325A
页数：1
相关论文
共 50 条
  • [21] Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients
    Lancet, J. E.
    Karp, J.
    Cripe, L.
    Roboz, G.
    Wollman, M.
    Berman, C.
    Conroy, A.
    Hawtin, R.
    Fox, J.
    Michelson, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Effective treatment of refractory and relapsed AML with the triple combination of mitaxantrone, topotecan and cytosin-arabinoside (MTC).
    Bergmann, L
    Heil, G
    Ganser, A
    Martin, H
    Rhagavachar, A
    Einsele, H
    Hoelzer, D
    Hoechsmann, B
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 588S - 588S
  • [23] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results
    Advani, Anjali S.
    Cooper, Brenda W.
    Visconte, Valeria
    Elson, Paul
    Chan, E. Ricky
    Carew, Jennifer
    Mukherjee, Sudipto
    Gerds, Aaron T.
    Carraway, Hetty E.
    Nazha, Aziz
    Hamilton, Betty K.
    Sobecks, Ronald
    Caimi, Paolo
    Tomlinson, Benjamin
    Malek, Ehsan
    Little, Jane A.
    Fensterl, Jaime
    Unger, Allison
    Zimmerman, Cassie
    Goebel, Christopher
    Hoxha, Nita
    Siebenaller, Caitlin
    Thomas, Jenna
    Rush, Mary Lynn
    Bogati, Samjhana
    Parsons, Eric
    Diligente, Rachael
    Kane, Donna
    Nielsen, Alek
    Hirsch, Cassandra M.
    Edelheit, Simone
    Miron, Alexander
    Pink, John
    Maciejewski, Jaroslaw P.
    Kalaycio, Matt
    De Lima, Marcos
    Sekeres, Mikkael A.
    BLOOD, 2017, 130
  • [24] Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
    Klisovic, Rebecca B.
    Wang, Hongyan
    Walker, Alison
    Walsh, Katherine
    Vasu, Sumithira
    Garzon, Ramiro
    Devine, Steven M.
    Wang, Jiang
    Garr, Celia
    Norris, Adam
    Byrd, John C.
    Grever, Michael R.
    Blum, William
    Chan, Kenneth K.
    Marcucci, Guido
    BLOOD, 2012, 120 (21)
  • [25] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study.
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Giles, FJ
    Koller, C
    Estey, E
    BLOOD, 1998, 92 (10) : 235A - 235A
  • [26] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia
    Advani, Anjali
    Elson, Paul
    Hsi, Eric D.
    Davis, Randall
    Kalaycio, Matt
    Sobecks, Ronald
    Copelan, Edward
    Duong, Hien K.
    Foster, Bethany
    Rush, Mary Lynn
    Farhat, Leslie
    Sekeres, Mikkael A.
    BLOOD, 2012, 120 (21)
  • [27] The Use of Clofarabine and Cytarabine Combination (CLARA) As Salvage Therapy for Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
    Leung, Anskar Y. H.
    Tse, Eric
    Liu, Herman S. Y.
    Sim, Joycelyn
    Kho, Bonnie C. S.
    Yip, Sze-Fai
    Lee, Harold K. K.
    Kwong, Yok Lam
    BLOOD, 2012, 120 (21)
  • [28] A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Kuchroo, Manik Razdan
    Redd, Robert A.
    Garcia, Jacqueline S.
    Keng, Michael
    Hobbs, Gabriela S.
    Rosenblatt, Jacalyn
    Luskin, Marlise R.
    Narayan, Rupa
    Amrein, Philip C.
    McMasters, Malgorzata
    Wadleigh, Martha
    Hock, Hanno
    Stone, Richard
    Neuberg, Donna S.
    Avigan, David
    Ballen, Karen K.
    Fathi, Amir T.
    DeAngelo, Daniel J.
    Brunner, Andrew M.
    BLOOD, 2023, 142
  • [29] Asciminib as a Bridge to Allogenic Transplant in 3 Patients With Relapsed/Refractory Philadelphia Chromosomepositive ALL or CML Lymphoid Blast Crisis Refractory/Intolerant to Ponatinib
    Kumar, Nikhil M.
    Bhargava, Rahul
    Rastogi, Neha
    Yadav, Chitresh
    Swaminathan, Anusha
    Garg, Paritosh
    Kothari, Akriti
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S283 - S284
  • [30] SALVAGE REGIMENT WITH FRACTIONATED GEMTUZUMAB OZOGAMICIN, INTERMEDIATE DOSE CYTARABINE AND MITOXANTRONE (MYLODAM) FOR REFRACTORY AND RELAPSED AML: A SINGLE CENTER EXPERIENCE
    Mamez, A. C.
    Hirsch, P.
    Isnard, F.
    Lapusan, S.
    Rubio, M. T.
    Grignano, E.
    Marzac, C.
    Vekhoff, A.
    Mohty, M.
    Legrand, O.
    HAEMATOLOGICA, 2015, 100 : 44 - 45
12345